Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Buchanan, R. W. Articles by Carpenter, W. T. Search for Related Content PubMed Citation Articles by Buchanan, R. W. Articles by Carpenter, W. T., Jr. Atypical Neuroleptics Conventional Neuroleptics Schizophrenia Spectrum Disorders

Olanzapine Treatment of Residual Positive and Negative Symptoms

OBJECTIVE: Olanzapine has been hypothesized to have superior efficacy in patients with treatment-resistant schizophrenia. The authors examined the comparative efficacy and safety of olanzapine and haloperidol in outpatients with partially responsive schizophrenia. METHOD: Sixty-three outpatients with schizophrenia who met retrospective and prospective criteria for either residual positive or residual negative symptoms entered a 16-week double-blind, parallel-groups comparison of olanzapine and haloperidol. RESULTS: There were no significant differences between the two drugs in their effect on positive or negative symptoms. There were no significant differences between the two treatment groups on measures of social and functional outcome. Olanzapine-treated patients had a significant reduction in extrapyramidal symptoms and subjective measures of stiffness and dry mouth, but the increases in systolic blood pressure and weight in olanzapine-treated patients were significantly greater than they were in haloperidol-treated patients. CONCLUSIONS: Olanzapine has limited differential benefit for either positive or negative symptoms in patients with treatment-resistant schizophrenia. Although olanzapine is associated with fewer extrapyramidal symptoms, other side effects may offset this benefit.

This article has been cited by other articles:

				J. Rabinowitz, S. Z. Levine, O. Barkai, and O. Davidov Dropout Rates in Randomized Clinical Trials of Antipsychotics: A Meta-analysis Comparing First- and Second-Generation Drugs and an Examination of the Role of Trial Design Features Schizophr Bull, July 1, 2009; 35(4): 775 - 788. [Abstract] [Full Text] [PDF]

				D. Kelly, E Weiner, M. Ball, R. McMahon, W. Carpenter, and R. Buchanan Remission in schizophrenia: the relationship to baseline symptoms and changes in symptom domains during a one-year study J Psychopharmacol, June 1, 2009; 23(4): 436 - 441. [Abstract] [PDF]

				J. Kreyenbuhl, S. C. Marcus, J. C. West, J. Wilk, and M. Olfson Adding or Switching Antipsychotic Medications in Treatment-Refractory Schizophrenia Focus, April 1, 2008; 6(2): 212 - 220. [Abstract] [Full Text] [PDF]

				J. Kreyenbuhl, S. C. Marcus, J. C. West, J. Wilk, and M. Olfson Adding or Switching Antipsychotic Medications in Treatment-Refractory Schizophrenia Psychiatr Serv, July 1, 2007; 58(7): 983 - 990. [Abstract] [Full Text] [PDF]

				R. W. Buchanan Persistent Negative Symptoms in Schizophrenia: An Overview Schizophr Bull, July 1, 2007; 33(4): 1013 - 1022. [Abstract] [Full Text] [PDF]

				Other articles noted Evid. Based Med., August 1, 2005; 10(4): 127 - 128. [Full Text] [PDF]

				L. de HAAN and N. van BEVEREN Olanzapine and Haloperidol for Residual Symptoms Am J Psychiatry, July 1, 2005; 162(7): 1392 - 1393. [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2005 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us